Biologics Contract Manufacturing Market

Biologics Contract Manufacturing Market (Biopharma CDMO / Biopharma CMO / Biologics Manufacturing): Industry Trends, Global and Regional Forecasts, till 2035: by Type of Service(s) Offered (API, FDF), Type of Biologic Manufactured (Antibodies, Cell Therapies, Vaccines and Other Biologics), Type of Expression System Used (Mammalian, Microbial and Others), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Small, Mid-sized, and Large and Very Large), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America and MENA)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    958

  • Pages
    799

  • View Count
    54838

Table Of Contents

1 PREFACE
1.1. Biopharmaceutical Contract Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
 
2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
 
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
 
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS 
3.1. Chapter Overview
3.2. Market Dynamics
 
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
 
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
 
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
 
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
 
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
 
4 EXECUTIVE SUMMARY
 
5 INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Biopharmaceuticals
5.3. Expression Systems for Biopharmaceuticals
5.3.1. Insect Expression Systems
5.3.2. Mammalian Expression Systems
5.3.3. Microbial Expression Systems
5.3.3.1. Bacterial Expression Systems
5.3.3.2. Fungal Expression Systems
5.3.3.3. Yeast Expression Systems
5.3.4. Plant Expression Systems
5.3.5. Mammalian versus Microbial Expression Systems 
 
5.4. Manufacturing Process of Biopharmaceuticals
5.4.1. Upstream Processing
5.4.2. Fermentation
5.4.3. Downstream Processing
 
5.5. Overview of Contract Manufacturing
5.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
5.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
5.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
5.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
5.7. Key Considerations While Selecting a Contract Manufacturing Partner
5.8. Future Perspectives 
 
6 MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of Service Offered
6.2.5. Analysis by Type of Biologic Manufactured
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Expression System Used
6.2.8. Analysis by Type of Bioreactor Used
6.2.9. Analysis by Mode of Operation of Bioreactor
 
7 REGIONAL CAPABILITY ANALYSIS
7.1.  Chapter Overview
7.2. Key Assumptions and Parameter 
7.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
7.3.1. Analysis by Type of Service Offered
7.3.2. Analysis by Scale of Operation
7.4.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
7.5.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
7.6.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
7.7.  Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
 
8 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
8.3. Leading Biopharmaceutical CMOs in North America
 
8.3.1. AGC Biologics
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.2.1. Process Development
8.3.1.2.2. cGMP Manufacturing
8.3.1.2.3. Quality and Regulatory Services
8.3.1.2.4. Process Validation
8.3.1.3. Financial Information
8.3.1.4. Manufacturing Facilities
8.3.1.5. Recent Developments and Future Outlook
8.3.2. Catalent
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.2.1. Cell Line Development
8.3.2.2.2. Biomanufacturing
8.3.2.2.3. ADCs and Bioconjugates Manufacturing
8.3.2.2.4. Biosimilars Development and Manufacturing
8.3.2.2.5. Fill / Finish Solutions and Delivery Services
8.3.2.2.6. Analytical Services
8.3.2.3. Clinical Supply Services
8.3.2.4. Financial Information
8.3.2.5. Manufacturing Facilities
8.3.2.6. Recent Developments and Future Outlook
 
8.3.3. FUJIFILM Diosynth Biotechnologies
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.2.1. Strain Development
8.3.3.2.2. Process Development
8.3.3.2.3. cGMP Manufacturing
8.3.3.2.4. Analytical Solutions
8.3.3.3. Financial Information
8.3.3.4. Manufacturing Facilities
8.3.3.5. Recent Developments and Future Outlook
 
8.3.4. KBI Biopharma
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.2.1. Process Development
8.3.4.2.2. Analytical Development
8.3.4.2.3. GMP Manufacturing
8.3.4.2.4. Clinical Cell Therapy Support
8.3.4.3. Manufacturing Facilities
8.3.4.4. Recent Developments and Future Outlook
 
8.3.5. Charles River Laboratories
8.3.5.1 Company Overview
8.3.5.2. Service Portfolio
8.3.5.2.1. Cell Sourcing
8.3.5.2.2. Cell and Gene Therapy Solutions
8.3.5.2.3. Biologics Testing Solutions
8.3.5.2.4. Avian Vaccine Services
8.3.5.2.5. QC Microbial Solutions
8.3.5.2.6. Scientific and Regulatory Advisory Services
8.3.5.3. Financial Information
8.3.5.4. Manufacturing Facilities
8.3.5.5. Recent Developments and Future Outlook
 
8.4. Other Leading Biopharmaceutical CMOs in North America
8.4.1. Cytiva
8.4.1.1. Company Overview
8.4.2. Patheon
8.4.2.1. Company Overview
8.4.3 Piramal Pharma Solutions
8.4.3.1. Company Overview
 
9 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
9.2.1. EMA’s cGMP Regulations 
 
9.3. Leading Biopharmaceutical CMOs in Europe
 
9.3.1. Boehringer Ingelheim (BioXcellence)
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.2.1. Process Development
9.3.1.2.1.1. Expression Systems
9.3.1.2.1.2. Upstream Technology
9.3.1.2.1.3. Downstream Technology
9.3.1.2.1.4. Other Process Development Services
9.3.1.2.2. Quality Assurance
9.3.1.2.3. Fill / Finish Services
9.3.1.3. Financial Information
9.3.1.4. Manufacturing Facilities
9.3.1.5. Recent Developments and Future Outlook
 
9.3.2. Lonza
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Services
9.3.2.4. Financial Information
9.3.2.5. Manufacturing Facilities
9.3.2.6. Recent Developments and Future Outlook
 
9.3.3. Sandoz
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Financial Information
9.3.3.4. Manufacturing Facilities
9.3.3.5. Recent Developments and Future Outlook
 
9.3.4. Vetter Pharma
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.3.4.3. Manufacturing Facilities
9.3.4.4. Recent Developments and Future Outlook

9.3.5. Miltenyi Biotec
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Manufacturing Facilities
9.3.5.4. Recent Developments and Future Outlook
9.4. Other Leading Biopharmaceutical CMOs in Europe
9.4.1 Novasep
9.4.1.1. Company Overview

9.4.2 Olon
9.4.2.1. Company Overview
9.4.3 Rentschler Biopharma
9.4.3.1. Company Overview
 
10 BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND REST OF THE WORLD
10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing in China
10.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
10.3. Leading Biopharmaceutical CMOs in China
10.3.1. WuXi Biologics
10.3.1.1. Company Overview
10.3.1.2. Service Portfolio
10.3.1.2.1. Discovery Services
10.3.1.2.2. Development Services
10.3.1.2.3. Testing Services
10.3.1.2.4. Clinical Manufacturing Services
10.3.1.3. Financial Information
10.3.1.4. Manufacturing Facilities
10.3.1.5. Recent Developments and Future Outlook
 
10.4. Biopharmaceutical Contract Manufacturing in India
10.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
 
10.5. Leading Biopharmaceutical CMOs in India
10.5.1. Kemwell Biopharma
10.5.1.1. Company Overview
10.5.1.2. Service Portfolio
10.5.1.2.1. Development Services for Biopharmaceuticals
10.5.1.2.2. Manufacturing Services for Biopharmaceuticals
10.5.1.3. Manufacturing Facilities
10.5.1.4. Recent Developments and Future Outlook
10.6. Biopharmaceutical Contract Manufacturing in Japan
10.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
10.7. Leading Biopharmaceutical CMOs in Japan
10.7.1. Minaris Regenerative Medicine
10.7.1.1. Company Overview
10.7.1.2. Service Portfolio
10.7.1.2.1. Manufacturing Development Services
10.7.1.2.2. GMP Manufacturing
10.7.1.3. Manufacturing Facilities
10.7.1.4. Recent Developments and Future Outlook
10.8. Biopharmaceutical Contract Manufacturing in South Korea
10.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
 
10.9. Leading Biopharmaceutical CMOs in South Korea
10.9.2. Samsung Biologics
10.9.2.1. Company Overview
10.9.2.2. Service Portfolio
10.9.2.2.1. Process Development
10.9.2.2.2. Analytical Services
10.9.2.2.3. cGMP Manufacturing Services
10.9.2.2.4. Aseptic Fill / Finish Services
10.9.2.2.5. Quality Services
10.9.2.3. Financial Information
10.9.2.4. Manufacturing Facilities
10.9.2.5. Recent Developments and Future Outlook
 
10.10. Biopharmaceutical Contract Manufacturing in Australia
10.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
 
10.11. Leading Biopharmaceutical CMOs in Australia
10.11.1. Cell Therapies
10.11.1.1. Company Overview
10.11.1.2. Service Portfolio
10.11.1.3. Manufacturing Facilities
10.11.1.4. Recent Developments and Future Outlook
 
10.12. Other Leading Biopharmaceutical CMOs in Asia-Pacific and Rest of the World
10.12.1 AcuraBio (Formerly Known as Luina Bio)
10.12.1.1. Company Overview
10.12.2 Celltrion
10.12.2.1. Company Overview
10.12.3 Takara Bio
10.12.3.1. Company Overview
 
11 NICHE BIOPHARMACEUTICAL SECTORS
11.1. Chapter Overview
11.2. Bispecific Antibodies
11.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
11.2.2. Bispecific Antibodies: Pipeline Analysis
11.2.2.1. Analysis by Phase of Development
11.2.2.2. Analysis by Target Indication
11.2.3. Bispecific Antibody Therapeutics: Technology Platforms
11.2.4. Key Considerations for Manufacturing and Associated Challenges
11.2.5. Role of  CMOs in Offering Services for Bispecific Antibodies
11.2.5.1. CMOs Offering Services for Bispecific Antibodies

11.3. Antibody Drug Conjugates (ADCs)
11.3.1. Components of ADCs
11.3.1.1. Antibody
11.3.1.2. Cytotoxin
11.3.1.3. Linker
11.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
11.3.2.1. Analysis by Status of Development
11.3.2.2. Analysis by Target Disease Indication
11.3.2.3. Most Active Players: Analysis by Number of Therapies
11.3.3. Antibody Drug Conjugate Developers
11.3.4. Manufacturing Process

11.4. Cell Therapies
11.4.5. Technical Challenges Related to Antibody Drug Conjugates Manufacturing
11.4.6. Role of  CMOs in Offering Services for ADCs
11.4.6.1. CMOs Offering Services for ADCs
11.4.1. Cell Therapies: Overall Market Landscape
11.4.2. Overview of Cell Therapy Manufacturing
11.4.2.1. Cell Therapy Manufacturing Models
11.4.2.1.1. Centralized Manufacturing
11.4.2.1.2. Decentralized Manufacturing
11.4.3. Key Challenges for Manufacturing Cell Therapies
11.4.4. Key Factors Impacting Cell Therapy Manufacturing
11.4.4.1. Characterization
11.4.4.2. Cost of Goods
11.4.4.3. Automation of Cell Therapy Manufacturing
11.4.5 Cell Therapies: Pipeline Analysis
11.4.5.1 Analysis by Type of Cell Manufactured
11.4.6. Stem Cell Therapies: Analysis by Phase of Development
11.4.7. T-Cell Therapies: Analysis by Phase of Development
11.4.8. Role of  CMOs in Offering Services for Cell Therapies
11.4.8.1. CMOs Offering Services for Cell Therapies
 
11.5. Gene Therapies 
11.5.1. Gene Therapies: Pipeline Analysis
11.5.1.1. Analysis by Stage of Development
11.5.1.2. Analysis by Phase of Development
11.5.1.3. Analysis by Type of Vector Used
11.5.1.3.1. Clinical Pipeline
11.5.1.3.2. Preclinical Pipeline
11.5.1.4. Analysis by Therapeutic Area
11.5.1.4.1. Clinical and Commercial Pipeline
11.5.1.4.2. Preclinical Pipeline
11.5.2. Role of  CMOs in Offering Services for Gene Therapies
11.5.2.1 CMOs Offering Services for Gene Therapies
 
11.6. Viral Vectors 
11.6.1. Viral Vectors: Pipeline Analysis
11.6.1.1. Analysis by Location of Viral Vectors Manufacturing Facilities
11.6.1.2.  Analysis by Type of Viral Vector Manufactured
11.6.2. Role of  CMOs in Offering Services for Viral Vectors
11.6.2.1. CMOs Offering Services for Viral Vectors
 
11.7. Plasmid DNA
11.7.1. Plasmid DNA: Pipeline Analysis
11.7.1.1. Analysis by Location of Manufacturing Facilities
11.7.2. Role of  CMOs in Offering Services for Plasmid DNA
11.7.2.1. CMOs Offering Services for Plasmid DNA
 
12 CASE STUDY: OUTSOURCING OF BIOSIMILARS
12.1. Chapter Overview
12.2. Overview of Biosimilars
12.3. Development Stages of Biosimilars
12.4. Regulatory Requirements for Licensing of Biosimilars
12.5. Need for Outsourcing Manufacturing Operations
12.6. Impact of Biosimilars on the Global Contract Manufacturing Market
12.6.1. Biosimilars: Historical Trend of FDA Approvals
12.7. Biosimilars Contract Manufacturing Service Providers
12.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations
 
13 CASE STUDY: COMPARISON OF SMALL AND  LARGE MOLECULE DRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of General Characteristics
13.2.2. Comparison of Key Specifications
13.2.3. Comparison of Manufacturing Process
13.2.4. Comparison of Key Manufacturing Challenges
 
14 CASE STUDY: IN-HOUSE MANUFACTURING
14.1. Chapter Overview
14.2. In-House Manufacturing
14.2.1. Benefits Associated with In-House Manufacturing
14.2.2. Risks Associated with In-House Manufacturing
14.3. Outsourcing Trends in the Biopharmaceutical Industry
14.3.1. Types of Outsourcing Partners
 
14.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
14.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing
 
15 MAKE VERSUS BUY DECISION MAKING FRAMEWORK
15.1. Chapter Overview
15.2. Key Assumptions and Parameters
 
15.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
15.3.1. Scenario 1
15.3.2. Scenario 2
15.3.3. Scenario 3
15.3.4. Scenario 4
15.4. Conclusion
 
16 BIG PHARMA INITIATIVES
16.1.  Chapter Overview
16.2.  Biopharmaceutical Related Initiatives by Big Pharmaceutical Players
16.2.1.  Analysis by Number of Initiatives
16.2.2.  Analysis by Year of Initiative
16.2.3. Analysis by Purpose of Initiative
16.2.4.  Analysis by Type of Initiative
16.2.4.1.  Analysis by Type of Partnership
16.2.4.2.  Analysis by Type of Expansion
16.2.5.  Analysis by Scale of Operation
16.2.6.  Analysis by Type of Biologic Manufactured
16.2.7. Analysis of Big Pharma Players by Year of Initiative
16.2.8. Analysis of Big Pharma Players by Purpose of Initiative
16.2.9.  Analysis by Year and Type of Initiative
16.2.10.  Analysis of Big Pharma Players by Region of Expansion
16.2.11. Analysis of Big Pharma Players by Type of Biologic Manufactured
 
17 PARTNERSHIPS AND COLLABORATIONS
17.1. Chapter Overview
17.2. Partnership Models
 
17.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
17.3.1. Analysis by Year of Partnership
17.3.2. Analysis by Type of Partnership
17.3.3. Analysis by Year and Type of Partnership
17.3.4. Analysis by Type of Biologic Manufactured
 
17.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
17.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
17.3.7. Analysis by Scale of Operation
17.3.8. Analysis by Therapeutic Area
17.3.9. Most Active Players: Analysis by Number of Partnerships
17.3.10. Analysis by Geography
17.3.10.1. Local and International Agreements
17.3.10.2.  Intracontinental and Intercontinental Agreements
 
18 MERGERS AND ACQUISITIONS
18.1. Chapter Overview 
18.2. Merger and Acquisition Models
18.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
18.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
18.3.2. Analysis by Type of Acquisition
18.3.3. Analysis by Geography
18.3.3.1. Local and International Mergers and Acquisitions
18.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
18.3.3.3. Year-wise Trend in North America, Europe and Asia-Pacific
18.3.4 Most Active Acquirers: Analysis by Number of Acquisitions
18.3.5 Analysis by Key Value Drivers
18.3.6. Analysis by Year of Acquisition and Key Value Drivers
18.3.7. Analysis by Type of Biologic Manufactured
18.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
18.4. Key Acquisitions: Deal Multiples
18.4.1. Year-wise Trend of Deal Multiple Amount
 
19 RECENT EXPANSIONS
19.1. Chapter Overview
19.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
19.2.1. Analysis by Year of Expansion
19.2.2. Analysis by Purpose of Expansion
19.2.3. Analysis by Year and Purpose of Expansion
19.2.4. Analysis by Type of Biologic Manufactured
19.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
19.2.6. Analysis by Location of Expanded Facility
19.2.7.  Most Active Players: Analysis by Number of Recent Expansions
19.2.8.  Analysis by Purpose of Expansion and Location of Expanded Facility
19.2.9. Analysis by Amount Invested
19.2.10.  Recent Expansions: 2016-2020 and 2021-2023 Scenario
 
20 RECENT DEVELOPMENTS
20.1. Chapter Overview
20.2. Types of Funding
20.3. Biopharmaceutical Contract Manufacturing: Funding and Investment Analysis
20.3.1. Analysis by Year of Funding
20.3.2. Analysis by Amount Invested
20.3.3. Analysis by Type of Funding
20.3.4. Analysis by Year and Type of Funding 
20.3.5. Analysis of Funding Instances and Amount Invested by Geography (Continent)
20.3.6. Analysis of Funding Instances and Amount Invested by Geography (Country)
20.3.7. Most Active Players: Analysis by Number of Funding Instances
20.3.8. Most Active Players: Analysis by Total Amount Raised 
20.3.9. Leading Investors: Analysis by Number of Funding Instances 
20.3.10. Leading Investors: Analysis by Total Amount Raised 
20.4. Technological Advancements
20.4.1. Single-Use Technology
20.4.2. Process Analytical Technology (PAT)
20.4.3. Continuous Processing
20.4.4. Quality by Design (QbD) in Bio-processing
20.4.5. Modular / Podular Biopharma Facilities
 
21 CAPACITY ANALYSIS
21.1.  Chapter Overview
21.2.  Key Assumptions and Methodology
21.3.  Biopharmaceutical Contract Manufacturing: Global Installed Capacity
21.3.1. Analysis by Company Size
21.3.2.  Analysis by Type of Expression System Used
21.3.3.  Analysis by Geography
21.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
 
21.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
21.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
21.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
21.4.  Concluding Remarks
 
22 DEMAND ANALYSIS
22.1.  Chapter Overview
22.2.  Key Assumptions and Methodology
22.3.  Global Demand for Biopharmaceuticals
22.4. Global Demand for Emerging Novel Biologics
22.4.1. Global Demand for ADC Therapeutics
22.4.2. Global Demand for Cell Therapy Manufacturing
 
23. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS 
23.1. Chapter Overview 
23.2. Key Parameters 
23.3. Assumptions and Methodology 
23.4. Total Cost of Ownership (Sample Dataset) 
23.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0 
23.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20 
 
23.7. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
23.7.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0 
23.7.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20 
 
24 GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.1. Scenario Analysis
24.3.1.1. Conservative Scenario
24.3.1.2. Optimistic Scenario
 
24.4. Key Market Segmentations
 
25 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
 
25.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035
25.3.1. API Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. FDF Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
25.4. Data Triangulation and Validation
 
26 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
 
26.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035
26.3.1. Antibodies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.2. Cell Therapies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.3. Vaccines: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
26.3.4. Other Biologics: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
26.4. Data Triangulation and Validation
 
27 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
 
27.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035
27.3.1. Mammalian Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.2. Microbial Expression Systems: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
27.3.3. Other Expression Systems: Historical Trends (2018-2022)  and Forecasted Estimates (2023-2035)
27.4. Data Triangulation and Validation
 
28 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
 
28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
28.3.1. Preclinical / Clinical Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
28.3.2. Commercial Operations: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
28.4. Data Triangulation and Validation
 
29 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
 
29.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
29.3.1. Small Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.2. Mid-sized Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
29.3.3. Large and Very Large Companies: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
29.4. Data Triangulation and Validation
 
30 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
 
30.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
30.3.1. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.1.1. US: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.1.2. Canada: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
30.3.2. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.1. Italy: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.2. Germany: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.3. France: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.4. Spain: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.5. UK: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.2.6. Rest of Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
30.3.3. Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.1. China: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.2. India: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.3. South Korea: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.4. Japan: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
 
30.3.4. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.3.5. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
30.8. Data Triangulation and Validation
 
31 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players
31.4. Data Triangulation and Validation
 
32 CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES
32.1. Chapter Overview
32.2. Historical Evolution of the Virtual Business Model
32.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
32.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
32.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers
 
33. SWOT ANALYSIS 
33.1 Chapter Overview
33.2. Strengths
33.3. Weaknesses
33.4. Opportunities
33.5. Threats
33.6. Comparison of SWOT Factors
33.7. Conclusion
 
34 FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
34.1. Chapter Overview
34.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
34.3. Shift from One-time Contracts to Strategic Partnerships
34.4. Integration / Adoption of  New and Innovative Technologies
34.4.1.  Single-use Bioreactors
34.4.2.  Novel Bioprocess Techniques
34.4.3.  Bioprocess Automation
 
34.5. Focus on Niche Therapeutic Areas
34.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
34.7. Capability Expansion by CMOs to become One-Stop-Shops
34.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
34.9. Increase in Financial Inflow and Outsourcing Budgets
34.10. Challenges Faced by Sponsors and Service Providers
34.10.1. Concerns Related to Single-use Systems
34.10.2. Issues Related to Capacity Fluctuations
34.11. Concluding Remarks
 
35 CONCLUSION
 
36 EXECUTIVE INSIGHTS
36.1. Chapter Overview
36.2. RoslinCT
36.2.1. Company Snapshot
36.2.2. Interview Transcript
 
36.3. Chapter Overview
36.3. JAFRAL Biosolutions
36.3.1. Company Snapshot
36.3.2. Interview Transcript
 
36.4. Chapter Overview
36.4. Discovery Life Sciences
36.4.1. Company Snapshot
36.4.2. Interview Transcript
 
36.5. Chapter Overview
36.5. Bioworkshops
36.5.1. Company Snapshot
36.5.2. Interview Transcript

36.6. Aldevron
36.6.1. Company Snapshot
36.6.2. Interview Transcript
 
36.7. Resilience
36.7.1. Company Snapshot
36.7.2. Interview Transcript
 
36.8. Minaris Regenerative Medicine
36.8.1. Company Snapshot
36.8.2. Interview Transcript
 
36.9. 53Biologics
36.9.1. Company Snapshot
36.9.2. Interview Transcript
 
36.10. Richter-Helm BioLogics
36.10.1. Company Snapshot
36.10.2. Interview Transcript
 
37 APPENDIX I: TABULATED DATA
 
38 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
 
39 APPENDIX III: DETAILS OF PARTNERSHIPS AND COLLABORATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology      
Figure 2.2 Research Methodology: Forecast Methodology      
Figure 2.3  Research Methodology: Robust Quality Control      
Figure 2.4  Research Methodology: Key Market Segmentation      
Figure 3.1  Lessons Learnt from Past Recessions      
Figure 4.1  Executive Summary: Overall Market Landscape      
Figure 4.2  Executive Summary: Regional Capability Analysis      
Figure 4.3  Executive Summary: Partnerships and Collaborations      
Figure 4.4  Executive Summary: Mergers and Acquisitions      
Figure 4.5  Executive Summary: Recent Expansions      
Figure 4.6  Executive Summary: Funding and Investment Analysis      
Figure 4.7  Executive Summary: Demand Analysis      
Figure 4.8  Executive Summary: Total Cost of Ownership      
Figure 4.9  Executive Summary: Market Forecast and Opportunity Analysis      
Figure 5.1  Types of Biopharmaceuticals      
Figure 5.2  Types of Expression Systems Used for the Production of Biopharmaceuticals      
Figure 5.3  Stages of the Biomanufacturing Process      
Figure 5.4  Types of Third-Party Service Providers      
Figure 5.5  Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations      
Figure 6.1  Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment      
Figure 6.2  Biopharmaceutical Contract Manufacturers: Distribution by Company Size      
Figure 6.3  Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)      
Figure 6.4  Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)      
Figure 6.5  Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region) Figure 6.6  Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered     
Figure 6.7  Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured      
Figure 6.8  Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)      
Figure 6.9  Biopharmaceutical Contract Manufacturers: Distribution by Type of  Biologic Manufactured and Company Size      
Figure 6.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation       
Figure 6.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation       
Figure 6.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used       
Figure 6.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)       
Figure 6.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used       
Figure 6.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of  Bioreactor      
Figure 7.1   Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities       
Figure 7.2  Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered       
Figure 7.3  Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation       
Figure 7.4  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in North America      
Figure 7.5  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in Europe     
Figure 7.6  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in Asia-Pacific      
Figure 7.7  Regional Capability Analysis: Biopharmaceutical Contract  Manufacturing Facilities in Rest of the World     
Figure 8.1  Biopharmaceutical Contract Manufacturing Industry: The US Market Scenario      
Figure 8.2  Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges      
Figure 8.3  US FDA Guidelines: Elements of a Quality Agreement      
Figure 8.4  US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations      
Figure 8.5  AGC Biologics: Annual Revenues, FY 2018-H1 FY 2023 (JPY Billion)      
Figure 8.6  Catalent: Service Portfolio       
Figure 8.7  Catalent: Biosimilars Service Portfolio      
Figure 8.8  Catalent: Annual Revenues, FY 2018-FY 2023 (USD Billion)      
Figure 8.9   FUJIFILM Diosynth Biotechnologies: Service  Portfolio      
Figure 8.10 FUJIFILM  Diosynth Biotechnologies: Annual  Revenues, FY 2018-FY 2022 (JPY Billion)     
Figure 8.11 FUJIFILM Holdings: Annual Revenues by Business  Divisions, FY 2022 (JPY Billion)      
Figure 8.12 KBI Biopharma: Service Portfolio       
Figure 8.13 Charles River Laboratories: Service Portfolio       
Figure 8.14 Charles River Laboratories: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)       
Figure 9.1  Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges      
Figure 9.2  EMA GMP Guidelines: Key Considerations for the Contract Giver, Contract Acceptor and the Contract      
Figure 9.3  Boehringer Ingelheim  (BioXcellenece): Service Portfolio     
Figure 9.4  Boehringer Ingelheim: Annual Revenues, FY 2018-H1 FY  2023 (EUR Billion)     
Figure 9.5  Lonza: Service Portfolio      
Figure 9.6  Lonza: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)      
Figure 9.7  Lonza: Annual Revenues by Business Divisions (CHF Billion)      
Figure 9.8 Sandoz: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)       
Figure 9.9 Vetter Pharma: Service  Portfolio      
Figure 10.1 Chinese Regulatory Guidelines: Key Considerations for the Contract Giver       
Figure 10.2 Chinese Regulatory Guidelines: Key Considerations for the Contract Acceptor       
Figure 10.3 Chinese Regulatory Guidelines: Key Aspects of the Contract       
Figure 10.5 WuXi Biologics: Service Portfolio       
Figure 10.6 Wuxi Biologics: Annual Revenues, FY 2018-H1 FY 2023 (RMB Billion)       
Figure 10.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers       
Figure 10.8 Kemwell Biopharma: Service Portfolio       
Figure 10.9 Minaris Regenerative Medicine: Service Portfolio       
Figure 10.10 Samsung Biologics: Service   Portfolio       
Figure 10.11 Samsung Biologics: Annual  Revenues, FY 2018-H1 FY 2023 (KRW Billion)       
Figure 10.12 Cell Therapies: Service   Portfolio       
Figure 11.1 Basic Structure of an Antibody       
Figure 11.2 Approved and Clinical  Bispecific Antibody Therapeutics: Distribution by Phase of Development      
Figure 11.3 Approved and Clinical  Bispecific Antibody Therapeutics:  Distribution by Target  Indication    
Figure 11.4 Structure of an Antibody Drug Conjugate (ADC)       
Figure 11.5 Antibody Drug Conjugates: Distribution by Status of Development       
Figure 11.6 Antibody Drug Conjugates: Distribution by Target Disease Indication      
Figure 11.7 Most Active Players: Distribution by Number of Therapies       
Figure 11.8 Decentralized Manufacturing: Process Model       
Figure 11.11 Cell Therapies: Challenges and Drivers       
Figure 11.10 Cell Therapies: Potency as Critical Quality Attribute       
Figure 11.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured       
Figure 11.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured       
Figure 11.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured       
Figure 11.14 Stem Cell Therapies:  Distribution by Phase of Development      
Figure 11.15 T-Cell Therapies: Distribution by Phase of Development       
Figure 11.16 Gene Therapies: Distribution by Stage of Development       
Figure 11.17 Gene Therapies: Distribution by Phase of Development       
Figure 11.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used       
Figure 11.19 Early-stage Pipeline of Gene  Therapies: Distribution by  Type of Vector Used      
Figure 11.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area       
Figure 11.21 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area       
Figure 11.22 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise)       
Figure 11.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured       
Figure 11.24 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility       
Figure 12.1 Manufacturing Stages of a Biosimilar Product       
Figure 12.2 Analytical and Functional Characterization Methods for Key Biosimilar Product       
Figure 12.3 Regulatory Process Adopted for Licensing of a Biosimilar  Product      
Figure 12.4 Need for Outsourcing  Biosimilar Manufacturing Operations      
Figure 12.5 Biosimilars: Historical Trend of  FDA Approvals, 2015-2022       
Figure 12.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations       
Figure 13.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022       
Figure 13.2 Small Molecules versus Large Molecules: Comparison of  Manufacturing Process      
Figure 14.1 Benefits Associated with In-House Manufacturing       
Figure 14.2 Risks Associated with In-House Manufacturing       
Figure 14.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships       
Figure 15.1 Make versus Buy Decision Making Framework       
Figure 15.2 Make versus Buy Decision Making Framework: Possible Scenarios       
Figure 16.1 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives      
Figure 16.2 Big Pharma Initiatives: Cumulative Year-wise Trend, Pre-2005-2023      
Figure 16.3 Big Pharma Initiatives: Distribution by Purpose of Initiative      
Figure 16.4 Big Pharma Initiatives: Distribution by Type of Initiative      
Figure 16.5 Big Pharma Initiatives: Distribution by Type of Partnership      
Figure 16.6 Big Pharma Initiatives: Distribution by Type of Expansion      
Figure 16.7 Big Pharma Initiatives: Distribution by Scale of Operation      
Figure 16.8 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured      
Figure 16.9 Big Pharma Initiatives: Distribution of Players by Year and Number of Initiatives      
Figure 16.10 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative       
Figure 16.11Big Pharma Initiatives: Distribution by Year  and Type of Initiative       
Figure 16.12Big Pharma Initiatives: Distribution of Players by Region of  Expansion        
Figure 16.13Big Pharma Initiatives: Distribution of Players by Type  of Biologic Manufactured       
Figure 17.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023       
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership       
Figure 17.3 Partnerships and  Collaborations: Distribution by Year and Type of Partnership     
Figure 17.4 Partnerships and  Collaborations: Distribution by Type of Biologic Manufactured     
Figure 17.5 Partnerships and  Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured    
Figure 17.6 Partnerships and  Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured    
Figure 17.7 Partnerships and  Collaborations: Distribution by Scale of Operation     
Figure 17.8 Partnerships and  Collaborations: Distribution by Therapeutic Area     
Figure 17.9 Most Active Players: Distribution by Number of  Partnerships     
Figure 17.10 Partnerships and Collaborations: Local and  International Agreements     
Figure 17.11 Partnerships and Collaborations: Intracontinental  and Intercontinental Agreements    
Figure 18.1 Mergers and Acquisitions: Year-Wise Cumulative Trend,  2015- 2023     
Figure 18.2 Mergers and Acquisitions:  Distribution by Type of  Acquisition     
Figure 18.3 Local and International  Mergers and Acquisitions      
Figure 18.4 Intracontinental and  Intercontinental Mergers and  Acquisitions     
Figure 18.5 Mergers and  Acquisitions: Year-Wise Trend  in North America, Europe and  Asia-Pacific (2015-2023)    
Figure 18.6 Most Active  Acquirers: Distribution by  Number of Acquisitions     
Figure 18.7 Catalent Biologics:  Information on Key  Acquisitions     
Figure 18.8 Mergers and  Acquisitions: Distribution by  Key Value Drivers     
Figure 18.9 Mergers and  Acquisitions: Distribution by  Year of Acquisition and Key  Value Drivers    
Figure 18.10 Mergers and  Acquisitions: Distribution by  Type of Biologic Manufactured     
Figure 18.11 Mergers and  Acquisitions: Distribution by  Key Value Drivers and Type of  Biologic Manufactured    
Figure 18.12 Mergers and  Acquisitions: Year-Wise Trend  of Deal Multiple Amount  (USD Million)    
Figure 19.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2023       
Figure 19.2 Recent Expansions: Distribution by Purpose of Expansion       
Figure 19.3 Recent Expansions: Distribution by Year and  Purpose of Expansion     
Figure 19.4 Recent Expansions: Distribution by Type of  Biologic Manufactured     
Figure 19.5 Recent Expansions: Distribution by Purpose of  Expansion and Type of  Biologic Manufactured    
Figure 19.6 Recent Expansions: Distribution by Location of  Expanded Facility     
Figure 19.7 Most Active Players: Distribution by Number of  Recent Expansions     
Figure 19.8 Recent Expansions: Distribution by Purpose of  Expansion and Location of  Expanded Facility    
Figure 19.9 Recent Expansions: Distribution by Amount  Invested (USD Million)      
Figure 19.10 Recent Expansions: Regional  Comparison 2016-2020 and  2021-2023 Scenario     
Figure 20.1 Funding and Investment  Analysis: Cumulative Year- wise Trend, 2016-2023     
Figure 20.2 Funding and Investment  Analysis: Cumulative Year- wise Trend  by Amount  Invested, 2016-2023 (USD  Million)  
Figure 20.3 Funding and Investment  Analysis: Distribution of  Funding Instances by Type of  Funding    
Figure 20.4 Funding and Investment  Analysis: Distribution of  Amount Invested by Type of  Funding (USD Million)     
Figure 20.5 Funding and Investment  Analysis: Distribution by Year  and Type of Funding     
Figure 20.6 Funding and Investment  Analysis: Distribution of  Funding Instances and Total  Amount Invested by  Geography (Continent) (USD  Million)  
Figure 20.7 Funding and Investment  Analysis: Distribution of  Funding Instances and Total  Amount Invested by  Geography (Country) (USD  Million)  
Figure 20.8 Most Active Players: Distribution by Number of  Funding Instances     
Figure 20.9 Most Active Players: Distribution by Total Amount  Raised (USD Million)     
Figure 20.10 Leading Investors: Distribution by Number of  Funding Instances     
Figure 20.11 Leading Investors: Distribution by Amount  Invested (USD Million)     
Figure 21.1 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size    
Figure 21.2 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used    
Figure 21.3 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities   
Figure 21.4 Biopharmaceutical Contract Manufacturing Capacity in  North America     
Figure 21.5 Biopharmaceutical Contract Manufacturing Capacity in  Europe     
Figure 21.6 Biopharmaceutical Contract Manufacturing Capacity in  Asia-Pacific     
Figure 21.8 Biopharmaceutical Contract Manufacturing Capacity in  Rest of the World    
Figure 22.1 Global Demand for Biopharmaceuticals, 2023-2035 (in kilograms)     
Figure 22.2 Global Demand for ADC Therapeutics, 2023-2035  (in kilograms)     
Figure 22.3 Global Demand for Cell Therapies, 2023-2035 (in terms of Number of Patients)     
Figure 22.4 Global Demand for Cell Therapies, 2023-2035 (Billion Cells)     
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)      
Figure 23.2 Total Cost of Ownership: Operational Expenditures  (OPEX)     
Figure 23.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20  (USD Million)   
Figure 23.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0:  Distribution by CAPEX (USD  Million)  
Figure 23.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20:  Distribution by OPEX (USD  Million)  
Figure 23.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract  Manufacturing Organizations, Y0-Y20 (USD Million)   
Figure 23.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract  Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)  
Figure 23.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract  Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)  
Figure 24.1 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022)    
Figure 24.2 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)   
Figure 24.3 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)   
Figure 24.4 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)   
Figure 25.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Type of  Service Offered, 2018, 2023  and 2035   
Figure 25.2 Biopharmaceutical Contract  Manufacturing Market for API Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion) 
Figure 25.3 Biopharmaceutical Contract  Manufacturing Market for FDF Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion) 
Figure 26.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Type of  Biologic Manufactured, 2018,  2023 and 2035   
Figure 26.2 Biopharmaceutical Contract  Manufacturing Market for Antibodies, Historical Trends (2018-2022) and Forecasted Estimates (USD Billion)
Figure 26.3 Biopharmaceutical Contract  Manufacturing Market for Cell Therapies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD  Billion)  
Figure 26.4 Biopharmaceutical Contract  Manufacturing Market for Vaccines, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD  Billion)  
Figure 27.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Type of  Expression System Used, 2018,  2023 and 2035   
Figure 27.2 Biopharmaceutical Contract  Manufacturing Market for Mammalian Expression Systems, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) 
Figure 27.3 Biopharmaceutical Contract  Manufacturing Market for Microbial Expression Systems, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) 
Figure 27.4 Biopharmaceutical Contract  Manufacturing Market for Other Expression  Systems, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion) 
Figure 28.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and  2035   
Figure 28.2 Biopharmaceutical Contract  Manufacturing Market for Preclinical / Clinical Operations, Historical Trends  (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Figure 28.3 Biopharmaceutical Contract  Manufacturing Market for Commercial Operations, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD  Billion) 
Figure 29.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035    
Figure 29.2 Biopharmaceutical Contract  Manufacturing Market for Small Companies, Historical  Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion) 
Figure 29.3 Biopharmaceutical Contract  Manufacturing Market for Mid- sized Companies, Historical Trends (2018-2022) and Forecasted  Estimates (2023- 2035) (USD Billion) 
Figure 29.4 Biopharmaceutical Contract  Manufacturing Market for Large and Very Large Companies, Historical Trends (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion) 
Figure 30.1 Biopharmaceutical Contract  Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035    
Figure 30.2 Biopharmaceutical Contract  Manufacturing Market in North America, Historical Trends  (2018-2022) and Forecasted Estimates (2023-2035) (USD  Billion)  
Figure 30.3 Biopharmaceutical Contract  Manufacturing Market in the US, Historical Trends (2018- 2022) and Forecasted Estimates  (2023-2035) (USD Billion)   
Figure 30.4 Biopharmaceutical Contract  Manufacturing Market in Canada, Historical Trends (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.5 Biopharmaceutical Contract  Manufacturing Market in  Europe, Historical Trends (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.6 Biopharmaceutical Contract  Manufacturing Market in Italy,  Historical Trends (2018-2022)  and Forecasted Estimates  (2023-2035) (USD Billion)   
Figure 30.7 Biopharmaceutical Contract  Manufacturing Market in Germany, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.8 Biopharmaceutical Contract  Manufacturing Market in France, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.9 Biopharmaceutical Contract  Manufacturing Market in Spain, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.10 Biopharmaceutical Contract  Manufacturing Market in the UK, Historical Trends  (2018- 2022) and Forecasted Estimates  (2023-2035) (USD Billion)  
Figure 30.11 Biopharmaceutical Contract  Manufacturing Market in Rest of Europe, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.12 Biopharmaceutical Contract  Manufacturing Market in Asia- Pacific, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.13 Biopharmaceutical Contract  Manufacturing Market in  China, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.14 Biopharmaceutical Contract  Manufacturing Market in India, Historical Trends (2018-2022)  and Forecasted Estimates  (2023-2035) (USD Billion)   
Figure 30.15 Biopharmaceutical Contract  Manufacturing Market in South  Korea, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.16 Biopharmaceutical Contract  Manufacturing Market in Japan, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)   
Figure 30.17 Biopharmaceutical Contract  Manufacturing Market in Rest of Asia-Pacific, Historical  Trends (2018-2022) and  Forecasted  Estimates (2023- 2035) (USD Billion) 
Figure 30.18 Biopharmaceutical Contract  Manufacturing Market in Latin  America, Historical Trends  (2018-2022) and Forecasted  Estimates (2023-2035) (USD  Billion)  
Figure 30.19 Biopharmaceutical Contract  Manufacturing Market in Middle East and North Africa,  Historical Trends (2018-2022)  and Forecasted Estimates  (2023-2035) (USD Billion)  
Figure 30.20 Biopharmaceutical Contract  Manufacturing Market:Distribution by Leading  Players (USD Billion)    
Figure 31.1 Overall Share of Virtual  Biopharmaceutical Companies in the Biopharmaceutical  Market (USD Billion)    
Figure 31.2 Overall Share of Virtual  Biopharmaceutical Companies in the Biopharmaceutical  Contract Manufacturing Market  in 2023 (USD Billion)   
Figure 32.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis     
Figure 32.2 Global Biopharmaceuticals  Market: Distribution of Number of FDA Approvals by  Year, 2005-2022    
Figure 32.3 Comparison of SWOT Factors:  Harvey Ball Analysis      
Figure 35.1 Concluding Remarks: Overall  Market Landscape      
Figure 35.2 Concluding Remarks: Partnerships and Collaborations     
Figure 35.3 Concluding Remarks: Mergers and Acquisitions      
Figure 35.4 Concluding Remarks: Funding and Investments      
Figure 35.5 Concluding Remarks: Recent Expansions      
Figure 35.6 Concluding Remarks: Capacity Analysis      
Figure 35.7 Concluding Remarks: Demand Analysis      
Figure 35.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)     
Figure 35.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)     

List Of Tables

Table 5.1 Mammalian versus Microbial Expression Systems
Table 6.1 List of Biopharmaceutical Contract Manufacturers
Table 6.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service Offered
Table 6.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Scale of Operation
Table 6.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression System Used
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 6.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 7.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 7.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 7.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific 
Table 7.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Biologics Manufacturing Facilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Catalent: Company Overview
Table 8.5 Catalent: Biologics Manufacturing Facilities
Table 8.6 Catalent: Recent Developments and Future Outlook
Table 8.7 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 8.8 FUJIFILM Diosynth Biotechnologies: Biologics Manufacturing Facilities
Table 8.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 8.10 KBI Biopharma: Company Overview
Table 8.11 KBI Biopharma: Biologics Manufacturing Facilities
Table 8.12 KBI Biopharma: Recent Developments and Future Outlook
Table 8.13 Charles River Laboratories: Company Overview
Table 8.14 Charles River Laboratories: Biologics Manufacturing Facilities
Table 8.15 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.16  Cytiva: Company Overview
Table 8.17  Patheon: Company Overview
Table 8.18  Piramal Pharma Solutions: Company Overview
Table 9.1 FDA Quality Agreements and EMA cGMP Regulations: A Comparative Analysis 
Table 9.2 Boehringer Ingelheim: Company Overview
Table 9.3 Boehringer Ingelheim: Biologics Manufacturing Facilities
Table 9.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 9.5 Lonza: Company Overview
Table 9.6 Lonza: Biologics Manufacturing Facilities
Table 9.7 Lonza: Recent Developments and Future Outlook
Table 9.8 Sandoz: Company Overview
Table 9.9 Sandoz: Biologics Manufacturing Facilities
Table 9.10 Sandoz: Recent Developments and Future Outlook
Table 9.11 Vetter Pharma: Company Overview
Table 9.12 Vetter Pharma: Biologics Manufacturing Facilities
Table 9.13 Vetter Pharma: Recent Developments and Future Outlook
Table 9.14 Miltenyi Biotec: Company Overview
Table 9.15 Miltenyi Biotec: Biologics Manufacturing Facilities
Table 9.16 Miltenyi Biotec: Recent Developments and Future Outlook
Table 9.17  Novasep: Company Overview
Table 9.18  Olon: Company Overview
Table 9.19  Rentschler Biopharma: Company Overview
Table 10.1 WuXi Biologics: Company Overview
Table 10.2 Wuxi Biologics: Biologics Manufacturing Facilities
Table 10.3 WuXi Biologics: Recent Developments and Future Outlook
Table 10.4 Kemwell Biopharma: Company Overview
Table 10.5 Kemwell Biopharma: Recent Developments and Future Outlook
Table 10.6 Minaris Regenerative Medicine: Company Overview
Table 10.7 Minaris Regenerative Medicine: Biologics Manufacturing Facilities
Table 10.8 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 10.9 Samsung BioLogics: Company Overview
Table 10.10 Samsung BioLogics: Biologics Manufacturing Facilities
Table 10.11 Samsung BioLogics: Recent Developments and Future Outlook
Table 10.12 Cell Therapies: Company Overview
Table 10.13 Cell Therapies: Recent Developments and Future Outlook
Table 10.14 AcuraBio: Company Overview
Table 10.15 Celltrion: Company Overview
Table 10.16 Takara Bio: Company Overview 
Table 11.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Phase of Development and Target Antigen
Table 11.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segment
Table 11.3 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 11.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 11.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 11.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 11.7 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indications and Therapeutic Areas
Table 11.8 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 11.9 ADC Contract Manufacturers: List of Companies
Table 11.10 Cell-based Therapies: Applications 
Table 11.11 Cell-based Therapies: Commercialized Products, 
Table 11.12 Key Cell Therapy Manufacturing Steps
Table 11.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.14 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 11.15 Cell Therapy Contract Manufacturers: List of Companies
Table 11.16 Gene Therapy Contract Manufacturers: List of Companies
Table 11.17 Vector and Gene Therapy Manufacturers (Non-Industry players): Information on Type of Vector Manufactured
Table 11.18 Viral Vectors Contract Manufacturers: List of Companies 
Table 11.19 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 11.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 12.1 List of Biosimilars Contract Manufacturing Service Providers 
Table 13.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 13.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 13.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 14.1 List of FDA Approved Biologics (2016-2022)
Table 16.1 Big Pharma Initiatives: List of Biopharmaceutical Manufacturing Initiatives 
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2019-2023
Table 17.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015-2023
Table 18.2 Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured
Table 18.3 Mergers and Acquisitions: Information on Deal Multiples, 2015-2023
Table 19.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions, 2016-2023
Table 20.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, 2016-2023
Table 20.2 Funding and Investment Analysis: Summary of Investments
Table 20.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 21.1 Biopharmaceutical Contract Manufacturers: Information on Capacity (Sample Data Set)
Table 21.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 21.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems (Sample Data Set)
Table 21.4 Capacity Analysis: Average Capacity for Microbial Expression Systems (Sample Data Set)
Table 21.5  Capacity Analysis: Average Capacity for Other Expression Systems (Sample Data Set)
Table 21.6 Capacity Analysis: Global Production Capacity
Table 22.1 Annual Biomanufacturing Capacity, 2023-2035 (Million Liters)
Table 23.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 23.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 31.1 List of Leading Biopharmaceutical Contract Manufacturing Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 36.1  RoslinCT: Key Highlights
Table 36.2  Jafral Biosolutions: Key Highlights
Table 36.3  Discovery Life Sciences: Key Highlights
Table 36.4  Bioworkshops: Key Highlights
Table 36.5  Aldevron: Key Highlights
Table 36.6  Resilience: Key Highlights
Table 36.7  Minaris Regenerative Medicine: Key Highlights
Table 36.8  53Biologics: Key Highlights
Table 36.9  Richter-Helm BioLogics: Key Highlights
Table 37.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 37.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 37.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 37.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 37.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Table 37.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 37.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 37.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Table 37.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of  Biologic Manufactured and Company Size
Table 37.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 37.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 37.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 37.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Table 37.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Table 37.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Table 37.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 37.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Table 37.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 37.19 AGC Biologics: Annual Revenues, FY 2018-H1 FY 2023 (JPY Billion)
Table 37.20 Catalent: Annual Revenues, FY 2018-FY 2023 (USD Billion)
Table 37.21 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
Table 37.22 FUJIFILM Holdings: Annual Revenues by Business Divisions FY 2022 (JPY Billion)
Table 37.23 Charles River Laboratories: Annual Revenues, FY 2018- H1 FY 2023 (USD Billion)
Table 37.24 Boehringer Ingelheim: Annual Revenues, FY 2018- H1 FY 2023 (EUR Billion)
Table 37.25 Lonza: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)
Table 37.26 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 37.27 Sandoz: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
Table 37.28 Wuxi Biologics: Annual Revenues, FY 2018-H1 FY 2023 (RMB Billion)
Table 37.29 Samsung Biologics: Annual Revenues, FY 2018-H1 FY 2023 (KRW Billion)
Table 37.30 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 37.31 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indications
Table 37.32 Antibody Drug Conjugates: Distribution by Status of Development
Table 37.33 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 37.34 Most Active Players: Distribution by Number of Therapies
Table 37.35 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Table 37.36 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 37.37 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 37.38 Stem Cell Therapies: Distribution by Phase of Development
Table 37.39 T-Cell Therapies: Distribution by Phase of Development
Table 37.40 Gene Therapies: Distribution by Stage of Development
Table 37.41 Gene Therapies: Distribution by Phase of Development
Table 37.42 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.43 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.45 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.46 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent)
Table 37.47 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 37.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 37.49 Biosimilars: Historical Trend of  FDA Approval, 2015-2022
Table 37.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022 
Table 37.51 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Table 37.52 Big Pharma Initiatives: Cumulative Year-wise Trend, Pre-2005-2023
Table 37.53 Big Pharma Initiatives: Distribution by Purpose of Initiative
Table 37.54 Big Pharma Initiatives: Distribution by Type of Initiative
Table 37.55 Big Pharma Initiatives: Distribution by Type of Partnership
Table 37.56 Big Pharma Initiatives: Distribution by Type of Expansion
Table 37.57 Big Pharma Initiatives: Distribution by Scale of Operation
Table 37.58 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Table 37.59 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Table 37.60 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 37.61 Big Pharma Initiatives: Distribution of Players by Region of Expansion 
Table 37.62 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2023
Table 37.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 37.64 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 37.65 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 37.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 37.67 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 37.68 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Table 37.69 Partnerships and Collaborations: Distribution by Scale of Operation
Table 37.70 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 37.71 Most Active Players: Distribution by Number of Partnerships
Table 37.72 Partnerships and Collaborations: Local and International Agreements
Table 37.73 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 37.74 Mergers and Acquisitions: Year-Wise Cumulative Trend, 2015-2023
Table 37.75 Mergers and Acquisitions: Distribution by Type of Agreement
Table 37.76 Mergers and Acquisitions: Intracontinental and Intercontinental Agreements 
Table 37.77 Mergers and Acquisitions: Local and International Agreements
Table 37.78 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia- Pacific (2015-2023)
Table 37.79 Most Active Acquirers: Distribution by Number of Acquisitions
Table 37.80 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 37.81 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 37.82 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 37.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 37.84 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Table 37.85 Recent Expansions: Cumulative Year-wise Trend, 2016-2023
Table 37.86 Recent Expansions: Distribution by Purpose of Expansion
Table 37.87 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 37.88 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 37.89 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 37.90 Recent Expansions: Distribution by Location of Expanded Facility
Table 37.91 Most Active Players: Distribution by Number of Recent Expansions
Table 37.92 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Table 37.93 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 37.94 Funding and Investment Analysis: Cumulative Year- wise Trend of Number of Funding Instances, 2016-2023
Table 37.95 Funding and Investment  Analysis: Cumulative Year- wise Trend of Total Amount Invested, 2016-2023 (USD Million)
Table 37.96 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding
Table 37.97 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 37.98 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 37.99 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Table 37.100 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Table 37.101 Most Active Players: Distribution by Number of Funding Instances
Table 37.102 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 37.103 Leading Investors: Distribution by Number of Funding Instances
Table 37.104 Leading Investors: Distribution by Total Amount Invested (USD Million)
Table 37.105 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Table 37.106 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Table 37.107 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Table 37.108 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 37.109 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 37.110 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 37.111 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 37.112 Global Demand for Biopharmaceuticals, 2023-2235 (in kilograms)
Table 37.113 Global Demand for ADC Therapeutics, 2023-2035 (in kilograms)
Table 37.114 Global Demand for Cell Therapies, 2023-2035 (in terms of Number of Patients)
Table 37.115 Global Demand for Cell Therapies, 2023-2035 (Billion Cells)
Table 37.116 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.117 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.118 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.119 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.120 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.121 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.122 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.123 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, 2023 and 2035 (USD Billion)
Table 37.124 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.125 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.126 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, 2023 and 2035 (USD Billion)
Table 37.127 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.128 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.129 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.130 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.131 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, 2023 and 2035 (USD Billion)
Table 37.132 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.133 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (2018-2022) and Forecasted   Estimates (2023-2035) (USD Billion)
Table 37.134 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.135 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035 (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.138 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035 (USD Billion)
Table 37.139 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.140 Biopharmaceutical Contract Manufacturing Market for Mid- sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.141 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.142 Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035 (USD Billion)
Table 37.143 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.144 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.145 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.146 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.147 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.148 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.149 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.150 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.151 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (2018- 2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.152 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.153 Biopharmaceutical Contract Manufacturing Market in Asia- Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.154 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.155 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.156 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.157 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.158 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023- 2035) (USD Billion)
Table 37.159 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.160 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Table 37.161 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Table 31.162 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Table 37.163 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2023
Table 39.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, 2015 – 2018

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

 

  1. 20Med Therapeutics
  2. 3P Biopharmaceuticals
  3. 3SBio
  4. 4D Pharma
  5. 4TEEN4 Pharmaceuticals
  6. 53Biologics
  7. Aalto Scientific
  8. AavantiBio
  9. AB2 Bio
  10. AbbVie
  11. Abcam
  12. AbCellera
  13. Abeona Therapeutics
  14. ABL Bio
  15. AbMax Biotechnology
  16. Abogen Biosciences
  17. Abpro
  18. Abzena
  19. AC Immune
  20. Acasti Pharma 
  21. Accelerated Biosciences
  22. Accellta
  23. Accinov
  24. ACES Pharma
  25. Achilles Therapeutics 
  26. ACT Therapeutics
  27. Acticor Biotech 
  28. AcuraBio (formerly Luina Bio)
  29. Adagene
  30. AdAlta
  31. Adaptimmune
  32. AdaptVac 
  33. Adare Pharma Solutions (formerly Aptalis Pharmatech)
  34. Adimmune
  35. Adimmune 
  36. ADL BioPharma
  37. Advanced BioScience Laboratories
  38. Advanced Biotherapeutics Consulting
  39. Advanced Cell Technology and Engineering
  40. Advaxia Biologics
  41. Advaxis
  42. Advent Bioservices 
  43. Advent International
  44. Affibody
  45. Affinita Biotech
  46. Affinity Life Sciences
  47. Afton Scientific
  48. AGC Biologics
  49. Agilis Biotherapeutics
  50. Airway Therapeutics
  51. Ajinomoto Bio-Pharma Services
  52. Akouos
  53. Akron Biotech
  54. Akshaya Bio
  55. Alaunos (formerly Ziopharm Oncology)
  56. Albumedix
  57. Alcami
  58. Alco Therapeutics
  59. Aldevron
  60. Alexion
  61. Alira Health
  62. AllCells
  63. Allele Biotechnology and Pharmaceuticals
  64. Allergy Therapeutics 
  65. Allevi 
  66. Alligator Bioscience
  67. Almac
  68. Almirall
  69. Alpine Immune Sciences
  70. Alteogen
  71. Altheia Science
  72. Altimmune
  73. Altor Bioscience
  74. Altruist Biologics
  75. Amaran Biotechnology
  76. Amatsigroup (Acquired by Eurofins)
  77. AmbioPharma
  78. Amgen
  79. Ampersand Capital Partners
  80. AM-Pharma
  81. Andelyn Biosciences
  82. Andes Biotechnologies
  83. Ankarys Therapeutics HebeCell
  84. ANL Bio
  85. Antabio
  86. Anthony Nolan
  87. Anthos Therapeutics
  88. apceth Biopharma
  89. Applied StemCell
  90. Aptevo Therapeutics
  91. AR BROWN
  92. Araris Biotech
  93. Aravive Biologics
  94. ARCALIS
  95. Arcellx
  96. Arch Biopartners
  97. ArchiMed
  98. ArcticZymes Technologies
  99. Arcturus Therapeutics
  100. Arcus Biosciences
  101. Arecor 
  102. Argenx
  103. Arranta Bio (Acquired by Recipharm)
  104. Aruvant Sciences
  105. Asahi Kasei
  106. ASC Therapeutics
  107. Ascend Gene & Cell Therapies
  108. Asher Biotherapeutics
  109. Asimov
  110. Asklepios BioPharmaceutical
  111. ASLAN Pharmaceuticals
  112. Aspire Health Science
  113. Astero Bio
  114. Astorg
  115. AstraZeneca
  116. Asymchem
  117. Atara Biotherapeutics
  118. Athenex
  119. Athersys
  120. aTyr Pharma
  121. Aumgene Biosciences
  122. Aurinia Pharmaceuticals
  123. Austrianova
  124. AutekBio
  125. Autolomous
  126. Autolus Therapeutics
  127. Avectas
  128. AveXis
  129. Avid Bioservices
  130. Avril Biopharma
  131. Axcelead Drug Discovery Partners
  132. Axcellerate Pharma
  133. Axovant Gene Therapies
  134. Babraham Bioscience Technologies
  135. Baccinex 
  136. Bachem 
  137. Bacthera
  138. Batavia Biosciences
  139. Battelle
  140. Bavarian Nordic
  141. Baxter
  142. Baxter BioPharma Solutions
  143. Bayer
  144. Baylor College of Medicine
  145. Baylor Institute for Immunology Research
  146. Baylor Scott & White Research Institute
  147. BBI Solutions
  148. BCN Peptides 
  149. Beam Therapeutics 
  150. BeiGene
  151. Beijing Hetang Shenghua Medical Technology
  152. Beijing Kawin Technology Share-Holding
  153. Bennu Biotherapeutics
  154. Berkeley Lights
  155. BeRNA Therapeutics
  156. Bexion Pharmaceuticals 
  157. Bhami Research Laboratory
  158. Bharat Biotech
  159. BIA Separations
  160. BianoGMP
  161. BIBITEC
  162. BiBo Pharma
  163. BINEX
  164. Bio Elpida
  165. Bio Farma
  166. Bio Immunitas
  167. Bioasis
  168. BioCell
  169. BioCentriq
  170. BioCina
  171. Biocon 
  172. BioConnection
  173. Biodextris
  174. Bio-Ess Laboratories
  175. Biofabri
  176. Biogen
  177. Bioingenium
  178. BioInno Bioscience
  179. Bioinova 
  180. BioInvent International
  181. Biological E.
  182. BioMARC
  183. Biomay
  184.  BioMeca
  185. Biomedical Advanced Research and Development Authority (BARDA)
  186. BiondVax Pharmaceuticals
  187. Bionova Scientific
  188. BioNTech
  189. Biopharma Global
  190. Bioqube Ventures
  191. Biosana Pharma
  192. BioSciencesCorp
  193. Biose Industrie
  194. BioSig Technologies
  195. Biosynth
  196. Bio-Synthesis
  197. BioTechnique
  198. Biotechpharma UAB
  199. BioTime
  200.  BioVaxys Technology
  201. BIOVECTRA
  202. Bioverativ
  203. Biovian
  204. Bioworkshops
  205. BioXcellence
  206. BioXpress Therapeutics
  207. BJ Bioscience
  208. BJP Laboratories
  209. Bliss Biopharmaceutical
  210. Bloom Science
  211. bluebird bio
  212. BlueJay Therapeutics
  213. Boehringer Ingelheim
  214. Boostimmune
  215. Bora Pharmaceuticals
  216. Boston Children’s Hospital
  217. Boston Institute of Biotechnology
  218. Boyalife
  219. French Tech Sovereignty
  220. BPL Biologics
  221. BrainEver
  222. BrainStorm Cell Therapeutics
  223. Brammer Bio
  224. Brenus Pharma
  225. BriaCell Therapeutics
  226. Bright Peak Therapeutics
  227. Bristol Myers Squibb
  228. Bryllan
  229. BSP Pharmaceuticals
  230. Burrard Pharmaceuticals
  231. Buzzard Pharmaceuticals AB
  232. C3i
  233. Caeregen Therapeutics
  234. Caisson Biotech
  235. Caladrius Biosciences
  236. California Institute for Regenerative Medicine (CIRM)
  237. Calviri
  238. Calypso Biotec
  239. CANbridge Pharmaceuticals
  240. Cancer Research Technology
  241. Cancer Research UK (University of Southampton)
  242. Canton Biologics
  243. CanVirex
  244. Capricor Therapeutics
  245. Captozyme
  246. CARBOGEN AMCIS
  247. CaroGen
  248. Catalent
  249. Catamaran Bio
  250. CDR-Life
  251. Cedar Pharmaceuticals
  252. Ceidos
  253. Cell and Gene Therapy Catapult
  254. Cell Culture Company
  255. Cell One Partners
  256. Cell Therapies
  257. Cellab
  258. Celladon 
  259. Cell-Easy
  260. Cellectis 
  261. Cellenion
  262. CellGenix
  263. Cellin Technologies
  264. CELLINK
  265. Cellipoint Bioservices (Formerly Performance Cell Manufacturing)
  266. Celltrion
  267. CelluGen Biotech
  268. Cellular Biomedicine Group
  269. Cellular Therapeutics
  270. Cellusion
  271. CellVax Therapeutics
  272. CellVec
  273. Celonic
  274. Celsion
  275. Cenexi
  276. Centaur Biopharmaceutical
  277. Center for Breakthrough Medicines
  278. Center for Innovation in Advanced Development and Manufacturing
  279. Centers for Disease Control and Prevention 
  280. Centre for Process Innovation
  281. CEPiA (Commercial & External Partnership, Industrial Affairs)
  282. Cerbios-Pharma
  283. Cerium Pharmaceuticals
  284. CEVEC Pharmaceuticals 
  285. Changchun High-tech
  286. Charles River Laboratories
  287. Cheerland Biotechnology
  288. Chemomab Therapeutics
  289. ChemPartner
  290. Children's Hospital of Philadelphia (CHOP)
  291. Chime Biologics
  292. Chimeron Bio
  293. China Regenerative Medicine International (CRMI)
  294. CHINAGENE
  295. Chinese Peptide Company
  296. Chiome Bioscience
  297. CHO Pharma
  298. Chong Kun Dang
  299. Chord Therapeutics
  300. Chr. Hansen
  301. CiMaas
  302. Cipla
  303. CiRA Foundation 
  304. Citryll
  305. Clean Biologics
  306. Clean Cells
  307. CMAB Biopharma
  308. CMC Biologics
  309. CMIC 
  310. Coalition for Epidemic Preparedness Innovations(CEPI)
  311. Coave Therapeutics
  312. Cobra Biologics
  313. Codagenix
  314. Cognate BioServices
  315. Coherus BioSciences
  316. CoJourney
  317. Columbia University
  318. CombiGene 
  319. Comprehensive Cell Solutions (CCS)
  320. Context Therapeutics
  321. Cook MyoSite
  322. CordenPharma
  323. Coretherapix
  324. CPC Scientific
  325. CPI
  326. CR Pharmaceutical
  327. CRC for Cell Therapy Manufacturing
  328. Creative Biogene
  329. Creative Biolabs
  330. CRISPR Therapeutics
  331. Cryoport
  332. CSBio
  333. CSL Seqirus
  334. CureCell
  335. CureVac
  336. Curia
  337. CyanVac
  338. Cytiva
  339.  CytoDyn
  340. CytoSen Therapeutics 
  341. Cytovance Biologics
  342. CyTuVax
  343. CZ Vaccines
  344. DAAN Biotherapeutics
  345. Daiichi Sankyo
  346. Dalton Pharma Services
  347. Danaher
  348. DanausGT Biotechnology
  349. DanDrit Biotech
  350. DaTaMabs
  351. Decibel Therapeutics
  352. Decipher Biosciences
  353. Delphi Genetics
  354. Denali Therapeutics 
  355. Dendreon
  356. Dendreon Pharmaceuticals
  357. DeoBioSciences
  358. Department of Defense
  359. DiNAMIQS
  360. DiNAQOR 
  361. DNDi
  362. Dongkook Pharmaceutical
  363. Dyadic International
  364. Dyax 
  365. Educell
  366. Eikonoklastes Therapeutics
  367. EirGenix
  368. Eisai
  369. Eli Lilly
  370. Emendo Biotherapeutics
  371. Emercell
  372. Emergent BioSolutions
  373. Emerson
  374. ENCell
  375. Encure Biopharma
  376. Enimmune
  377. Enleofen Bio 
  378. Enterobiome
  379. Enzene Biosciences
  380. Enzolytics
  381. ERC Belgium
  382. ERS Genomics
  383. Erytech Pharma
  384. Esco Aster
  385. Etinpro
  386. EuBiologics
  387. EUCODIS Bioscience
  388. EUFETS 
  389. EUROAPI
  390. Eurocine Vaccines
  391. Eurogentec 
  392. Eurofins
  393. Evanoa Bioscience
  394. EVER Pharma
  395. evitria
  396. Evologic Technologies
  397. Evotec
  398. EXCELLGENE
  399. Excellos
  400. ExCellThera
  401. Exelead
  402. Exelixis
  403. Exothera
  404. Expression Therapeutics
  405. FairJourney Biologics
  406. FamiCord
  407. Fapon Biopharma
  408. Farmabios
  409. Faron Pharmaceuticals
  410. FinVector
  411. Flagship Pioneering
  412. Flash Therapeutics
  413. FloDesign Sonics
  414. FluGen
  415. Forecyte Bio
  416. Forge Biologics
  417. Formycon
  418. For?Robin
  419. Forum for Innovative Regenerative Medicine 
  420. Fred Hutchinson Cancer Research Center
  421. Freeline Therapeutics
  422. Fresenius Kabi
  423. FUJIFILM Diosynth Biotechnologies
  424. Fusion Antibodies
  425. GAIA BioMedicine
  426. Gamida Cell
  427. GBI (Formerly Goodwin Biotechnology)
  428. GC Cell 
  429. GC Pharma
  430. GE Healthcare
  431. Gedeon Richter
  432. GemPharmatech
  433. GeneCraft
  434. GeneCure Biotechnologies
  435. Genenta Science
  436. Genentech
  437. GeneOne Life Sciences
  438. Geneos Therapeutics
  439. GeneQuantum Healthcare
  440. GeneQuine Biotherapeutics
  441. Genethon
  442. Genexine
  443. Genezen
  444. GenIbet Biopharmaceuticals
  445. Genmab
  446. Genome & Company
  447. Genopis
  448. Genovior 
  449. Genprex
  450. GenScript ProBio
  451. GenSensor
  452. GentiBio
  453. Genuv
  454. GigaGen
  455. Gilead Sciences
  456. Ginkgo Bioworks
  457. Gladstone
  458. Gland Pharma
  459. GHO Capital
  460. GlycoSeLect 
  461. Government of Canada
  462. Government of Europe
  463. Government Pharmaceutical Organization (Thailand)
  464. GP Pharm
  465. Grand River Aseptic Manufacturing (GRAM)
  466. Great Ormond Street Hospital for Children
  467. Great Point Partners
  468. Green Cross LabCell
  469. GreenLight Biosciences
  470. GreenPak Biotech
  471. Greffex
  472. Grenoble Hospital 
  473. Griffith University
  474. GSK
  475. GTP Bioways (formerly VBI Therapeutics)
  476. GTP Technology
  477. Gubra
  478. HaemaLogiX
  479. HALIX 
  480. Hangzhou Redox BIO
  481. Hanmi Pharmaceutical
  482. Hansa Biopharma 
  483. Harbin Hou pu Tong tang Biotechnology 
  484. Harbour BioMed
  485. Harpoon Therapeutics
  486. Harvard University
  487. HDT Bio
  488. Heidelberg Pharma
  489.  Helixmith
  490. Helvetic BioPharma
  491. Hemogenyx
  492. Hepatic Cell Therapy Support
  493. Hikma Pharmaceuticals
  494. Hile Bio-Technology
  495. Hilleman Laboratories
  496. Histocell (Acquired by Noray)
  497. Hitachi
  498. HiTech Health
  499. HK inno.N
  500. Hong Kong Institute of Biotechnology
  501. Hookipa Biotech
  502. Horizon Discovery 
  503. Horizon Pharma
  504. Horizon Therapeutics
  505. Houston Methodist Research Institute
  506. Hubei Yuyang Pharmaceutical
  507. Humanigen
  508. Hummingbird Bioscience
  509. Hybio Pharmaceutical
  510. Hycult Biotech
  511. HYGEIA
  512. IAVI 
  513. IBC Generium
  514. IBI-Lorenzini
  515. Icagen
  516. Ichnos Sciences
  517. ID Pharma
  518. IDT Biologika
  519. Ikarovec
  520.  I-Mab Biopharma
  521. Immatics
  522. Immune Pharmaceuticals
  523. Immunitas Therapeutics
  524. ImmunoCellular Therapeutics
  525. Immunocore
  526. ImmunoGenesis
  527. Immunome 
  528. Immunomedics
  529. ImmunoTek Bio Centers
  530. Immutep (formerly Prima Biomed)
  531. Imperial College London
  532. Imperial Innovations
  533. In3Bio
  534. INADcure Foundation
  535. IncoCell Tianjin
  536. Indapta Therapeutics
  537. Indian Immunologicals
  538. IndyGeneUS AI
  539. InflaRx
  540. Inhibrx
  541. InnoBation Bio
  542. Innoputix
  543. Innovative Biotech
  544. Innovative NeuroTechnologies
  545. InnovaVector
  546.  Inovio Pharmaceuticals
  547. Inpac Probiotics 
  548. INSERM-ANRS
  549. Insight68
  550. Institut Pasteur de Dakar
  551. Institute for Research
  552. Integrated DNA Technologies
  553. Integrity Bio
  554. IntellectiveBio
  555. International AIDS Vaccine Initiative 
  556. International Consortium
  557. International Stem Cell Corporation
  558. International Vaccine Institute (IVI)
  559. Intervacc
  560. Invetech
  561. Iovance Biotherapeutics
  562. iProgen Biotech
  563. IQVIA
  564. IsoPlexis
  565. Italian Biochemical Institute Giovanni Lorenzini
  566. IUCT Oncopole
  567. Iveric Bio
  568. Ixaka
  569. JAFRAL
  570. Japan Tissue Engineering
  571. Japanese Society for Regenerative Medicine
  572. Jeneil Biotech
  573. JHL Biotech
  574. Jiangsu Puxin Biopharmaceutical
  575. Jikei University School of Medicine
  576. Jitsubo 
  577. Jo Lab
  578. John Hopkins University
  579. Johnson & Johnson
  580. JOINN Biologics
  581. JOINN Laboratories
  582. Jubilant HollisterStier
  583. Juno Pharmaceuticals
  584. Junshi Biosciences
  585. Just Biotherapeutics
  586. Just-Evotec Biologics
  587. JW CreaGene
  588. JW Therapeutics
  589. KABS Laboratories
  590. KAHR Medical
  591. Kamat Pharmatech
  592. Kanaph Therapeutics
  593. Kanda BioTech
  594. Kaneka Eurogentec
  595. Karolinska Institutet 
  596. KBI Biopharma
  597. Kemwell Biopharma
  598. Kiadis Pharma 
  599. Kidswell Bio
  600. Kineta
  601. Kite Pharma
  602. Kodiak Sciences
  603. KOLON Life Science
  604. KP Pharmaceutical Technology
  605. KPC
  606. KriSan Biotech
  607. KUBio
  608. Kun Tuo Medical Research and Development
  609. KURE.AI
  610. Kytopen
  611. Labcorp
  612. Laboratorios Zepol
  613. Lacer 
  614. LakePharma
  615. LamKap Bio
  616. LAMPIRE Biological Laboratories
  617. Landau Biotechnology
  618. LaNova Medicines
  619. Lava Therapeutics
  620. Leads Biolabs
  621. Leanbio
  622. LEUKOCARE
  623. Levena Biopharma
  624. L-GAM
  625. Li Xiulan
  626. Life Biosciences
  627. Lifera
  628. LIfT BioSciences
  629. Liminal BioSciences (formerly Prometic Life Sciences)
  630. Limula
  631. lino Biotech
  632. Lipum 
  633. List Biological Laboratories
  634. LNC Therapeutics
  635. LogicBio Therapeutics
  636. Lokon Pharma
  637. LongBio
  638. Lonza
  639. LOTTE BIOLOGICS
  640. Lubrizol Life Science
  641. LucasPye BIO
  642. Luina Bio
  643. Lupin
  644. Lykan Bioscience
  645. Lyophilization Services of New England
  646. Lyophilization Technology
  647.  Lysogene
  648. Mabion
  649. MabPlex
  650. MAbSilico
  651. Mab-Venture Biopharma
  652. mAbxience
  653. MacroGenics
  654. Malvern Panalytical
  655. Massachusetts Eye and Ear
  656. Massachusetts Institute of Technology (MIT)
  657. MassBiologics
  658. MaSTherCell
  659. Matica Biotechnology
  660. Max Planck Society, University Medical Center Göttingen
  661. MaxiVAX
  662. Mayo Clinic
  663. MD Anderson Cancer Center (The University of Texas)
  664. Medeor Therapeutics
  665. Medical Technologies Innovation Facility
  666. Medigene
  667. MedImmune
  668. MEDINET
  669. MEDIPOST
  670. Medisun Holdings
  671. Medix Biochemica
  672. Meissa Vaccines
  673. Memo Therapeutics
  674. Menarini Biotech
  675. Mendus
  676. Merck
  677. Merck Millipore
  678. Meridian BioGroup
  679. Meridian Bioscience
  680. Meridian Life Science
  681. Mesoblast
  682. Metastagen
  683. Meteoric Biopharmaceuticals
  684. MGB Biopharma
  685. Microbiome Therapeutics Innovation Group (MTIG)
  686. MicroBiopharm Japan
  687. MicrofluidX
  688. Mila’s Miracle Foundation
  689. MilliporeSigma
  690. Milner Therapeutics Institute
  691. Miltenyi Biotec
  692. Minaris Regenerative Medicine
  693. Minneapolis Medical Research Foundation 
  694. Mitsubishi Gas Chemical Company
  695. mk2 Biotechnologies, Technical University of Munich (TUM)
  696. Moderna
  697. Molecular Partners 
  698. Morphotek
  699. Multispan
  700. Multiverse Pharma
  701. Mundipharma
  702. Mustang Bio
  703. Mycenax Biotech
  704. Mylab Discovery Solutions
  705. Myrtelle
  706. NAGASE & CO.
  707. Najít Technologies
  708. Namocell
  709. Nan Fung
  710. Nanotein Technologies
  711. Naobios
  712. National Cancer Institute
  713. National Center for Advancing Translational Sciences 
  714. National Center for Regenerative Medicine
  715. National Health Research Institutes 
  716. National Heart, Lung and Blood Institute
  717. National Institute of Allergy and Infectious Diseases 
  718. National Institute of Health (NIH)
  719. National Resilience
  720. Nature Technology
  721. Navrogen
  722. NBE-Therapeutics
  723. Neogen TC
  724. NeoProgen
  725. Neovacs
  726. NeoVentures Biotechnology 
  727. Neuland Laboratories
  728. NeuroFx
  729. NEUWAY Pharma 
  730. NextCell Pharma
  731. Nikon CeLL innovation
  732. Nitto Avecia
  733. NIZO
  734. Nobelpharma
  735. North Carolina State University
  736. Northway Biotech
  737. Nouscom
  738. NovalGen
  739. Novartis
  740. Novasep
  741. Novavax
  742. Novex Innovations
  743. NovoCodex Biopharmaceuticals
  744. Novozymes
  745. Nucleus Biologics
  746. Numab Therapeutics
  747. Nykode Therapeutics
  748. NYU Langone Health
  749. OBI Pharma
  750. OBiO Technology
  751. Octane Biotech
  752. Ocugen
  753. Oculogenex
  754. Odimma Therapeutics
  755. Odylia Therapeutics
  756. Ology Bioservices
  757. Olon
  758. Omeros  
  759. OmniaBio
  760. Oncodesign
  761. OncoOne
  762. OncoQuest
  763. OncoResponse
  764. OncoVent
  765. Ondek
  766. Ono Pharmaceutical
  767. OPM Biosciences
  768. Oragenics
  769. Orchard Therapeutics
  770. Orgenesis 
  771. Osaka University
  772. OSE Immunotherapeutics
  773. Osivax 
  774. Otsuka Pharmaceutical
  775. Oxford BioMedica
  776. Oxford BioTherapeutics
  777. Oxford Genetics
  778. Oxford MEStar 
  779. OXGENE
  780. Pace Life Sciences
  781. PackGene Biotech
  782. PaizaBio
  783. Pall
  784. Panacea Biotec
  785. Panacea Pharmaceuticals
  786. PanCELLa
  787. Panolos Bioscience
  788. Paragon Bioservices
  789. Paras Biopharmaceuticals
  790. Parker Institute for Cancer Immunotherapy
  791. Passage Bio
  792. PATH
  793. PCI Pharma Services
  794. PCT
  795. Peking University Biologics
  796. Peter MacCallum Cancer Centre
  797. Petrovax
  798. Pfizer
  799. Pfizer CentreOne
  800. Phanes Therapeutics
  801. PharmAbcine
  802. PharmaBio
  803. PharmaCell
  804. Pharmadule Morimatsu
  805. PharmaZell
  806. Pharmicell
  807. PhaseBio Pharmaceuticals
  808. pHion Therapeutics
  809. Pierre Fabre
  810. Pinteon Therapeutics
  811. Pionyr Immunotherapeutics
  812. Piramal Pharma Solutions
  813. PlasmidFactory
  814. Pluristyx
  815. Polaris Pharmaceuticals 
  816. Polpharma Biologics
  817. POLYGON Therapeutics
  818. Polyplus
  819. POLYVAC
  820. Portola Pharmaceuticals
  821. Porton Advanced Solutions
  822. Precirix 
  823. Precision NanoSystems
  824. Prestige Biologics
  825. Prevail Therapeutics
  826. Probiodrug
  827. ProBioGen
  828. Profacgen
  829. Profectus BioSciences
  830. Prokarium
  831. Propanc Biopharma
  832. Proteon Therapeutics
  833. ProteoNic
  834. Protexin
  835. Provia Labs
  836. PsiVac
  837. PTC Therapeutics 
  838. PX'Therapeutics
  839. Quantoom Biosciences
  840. Quell Therapeutics
  841. Quratis
  842. Radimmune Therapeutics
  843. Rani Therapeutics
  844. Rare Trait Hope Fund
  845. Ray Therapeutics
  846. RD-Biotech
  847. Recipharm
  848. Refana
  849. ReForm Biologics
  850. REGENXBIO
  851. Regulus Therapeutics
  852. ReiThera
  853. Relief Therapeutics
  854. Remedium Bio
  855. ReNeuroGen
  856. Rentschler Biopharma
  857. Rentschler Fill Solutions
  858. Replicate Bioscience
  859. Resilience
  860. Resolution Therapeutics
  861. RevaTis
  862. Revolo Biotherapeutics
  863. RheinCell Therapeutics
  864. RiboBio
  865. Richter-Helm BioLogics
  866. River Vision Development 
  867. Roche Diagnostics
  868. Rocket Pharmaceuticals
  869. Rokote Laboratories Finland
  870. RoosterBio
  871. Roslin Cell Therapies 
  872. RoslinCT
  873. Royaltech Med
  874. RVAC Medicines
  875. Rznomics
  876. SAB Biotherapeutics
  877. Saiba Biotech
  878. Sam Chun Dang Pharm
  879. Samsung Bioepis
  880. Samsung Biologics
  881. SanBio
  882. Sandoz
  883. Sanofi
  884. San Raffaele Hospital
  885. Santen Pharmaceutical
  886. Sarepta Therapeutics
  887. Sartorius Stedim Biotech
  888. SBT Instruments
  889. Scancell
  890. SCD
  891. School of Chemical Engineering (part of University of Adelaide)
  892. Scientific Protein Laboratories
  893. ScinoPharm
  894. Scorpion Biological Services
  895. SD Biosensor
  896. Selecta Biosciences
  897. Selexis
  898. Serendex Pharmaceuticals
  899. Serum Institute of India
  900. Servier
  901. SGS
  902. Shandong Luoxin Pharmaceutical
  903. Shanghai Jiao Tong University
  904. Sheba Medical Center 
  905. Shenyang Sino-German Equipment Park
  906. Shenzhen JYMed Technology
  907. Shilpa Biologicals
  908. Shire 
  909. Shoreline Biosciences
  910. Showa Denko
  911. Siam Bioscience
  912. Siegfried
  913. SillaJen
  914. Simris
  915. Singota Solutions
  916. Singzyme
  917. Sino-German International Industrial Park
  918. Sinorda Biomedicine
  919. SIRION Biotech
  920. Sistemic
  921. SJL Partners
  922. SK bioscience
  923. Smart Cells Holdings
  924. Snapdragon Chemistry
  925. Sofpromed
  926. Solid Biosciences
  927. Sonnet BioTherapeutics 
  928. Sorrento Therapeutics
  929. Southern RNA 
  930. Spicona
  931. SpyBiotech
  932. ST Pharm
  933. Stand Up Therapeutics
  934. Stanford University School of Medicine
  935. STCube
  936. Stelis Biosource
  937. Stellar Biotechnologies
  938. Stemmatters
  939. Sterling Pharma Solutions
  940. STgen Bio
  941. Stoic Bio
  942. Stratophase  
  943. Sumagen
  944. Sumitomo Dainippon Pharma
  945. Summa Life Sciences
  946. Sun Pharma
  947. Surface Oncology 
  948. Surrozen
  949. Suzhou Kintor Pharmaceuticals
  950. Suzhou Royaltech Med
  951. SwiftScale Biologics
  952. Symbiosis Pharmaceutical Services
  953. Symphogen
  954. Synaffix
  955. SynCo Bio
  956. Synimmune
  957. Synklino
  958. Synpromics
  959. Synthace
  960. Synthelis
  961. TaiMed Biologics
  962. Taiwan Bio Therapeutics
  963. Taiwan Liposome Company
  964. Takara Bio
  965. Takeda
  966. Takeda Pharmaceuticals
  967. Taron Solutions
  968. TCR2 Therapeutics
  969. TechInvention Lifecare
  970. Tectron 
  971. Telix Pharmaceuticals
  972. Tenboron
  973. TetraScience
  974. Teva Pharmaceuticals
  975. Tevogen Bio
  976. Texcell
  977. TG Therapeutics
  978. The Coalition for Epidemic Preparedness Innovations 
  979. The International Vaccine Institute (IVI)
  980. The Leukemia & Lymphoma Society
  981. The Michael J. Fox Foundation
  982. The New Hope Research Foundation
  983. The Parker Institute for Cancer Immunotherapy (PICI)
  984. The Peter Doherty Institute for Infection and Immunity
  985. The University Medical Center Göttingen (UMG)
  986. The University of Adelaide
  987. The University of Manchester
  988. The US Department of Defence
  989. Vistria Group
  990. The Wistar Institute
  991. Themis
  992. Theracell Advanced Biotechnology
  993. Theragent
  994. Theramex
  995. Therapure Biopharma
  996. Theravectys
  997. Thermo Fisher Scientific
  998. Boway Biotech Joint Antibody Engineering Technology Display and Service Center (a     part of Thermo Fisher Scientific)
  999. ThermoGenesis (formerly known as Cesca Therapeutics)
  1000. Thousand Oaks Biopharmaceuticals
  1001. Tianjin Pharmaceutical
  1002. TiGenix
  1003. Tillotts Pharma 
  1004. Tizona Therapeutics
  1005. T-knife
  1006. Tmunity Therapeutics
  1007. Tonix Pharmaceuticals
  1008. Toregem BioPharma
  1009. Touchlight
  1010. Touchlight Genetics
  1011. TRACON Pharmaceuticals
  1012. TrakCel
  1013. Transgene
  1014. Translate Bio
  1015. Transporin
  1016. TranXenoGen
  1017. Treadwell Therapeutics
  1018. Trefoil Therapeutics 
  1019. Trellis Bioscience
  1020. Trianni
  1021. Trieza Therapeutics
  1022. Tri-Institutional Therapeutics Discovery Institute 
  1023. TriLink BioTechnologies
  1024. TRIO Pharmaceuticals
  1025. Triphase Accelerator 
  1026. Trizell
  1027. Tsinghua University Innovation Center for Immune Therapy 
  1028. TUBE Biopharmaceuticals
  1029. TWi Pharmaceuticals
  1030. Twist Bioscience
  1031. TxCell
  1032. U.S. Department of Defense
  1033. uBriGene Biosciences
  1034. UGA Biopharma
  1035. UK Cystic Fibrosis Gene Therapy Consortium
  1036. UK Dementia Research Institute
  1037. UK Government
  1038. Ultragenyx Pharmaceutical
  1039. UNC Lineberger Comprehensive Cancer Center
  1040. Unique Biotech
  1041. Univercells
  1042. Univercells Technologies
  1043. University College London
  1044. University of Aberdeen
  1045. University of Birmingham
  1046. University of California
  1047. University of Leeds
  1048. University of Pennsylvania
  1049. University of Queensland
  1050. University of Reading
  1051. University of Sheffield
  1052. University of South Australia 
  1053. University of Tokyo 
  1054. Uppsala BIO
  1055. US Department of Defense
  1056. US government 
  1057. Vaccine Manufacturing and Innovation Centre
  1058. Vaccine Research Institute (VRI)
  1059. Vaccitech 
  1060. Vaccizone
  1061. ValenzaBio
  1062. Valerius Biopharma
  1063. Valneva 
  1064. Valo Health
  1065. Valo Therapeutics
  1066. Vanderbilt University Medical Center 
  1067. Vasculogics
  1068. Vaxart
  1069. VBI Vaccines
  1070. VDDI Pharmaceuticals
  1071. Vector BioMed
  1072. VectorBuilder 
  1073. Vectron Biosolutions
  1074. Veeva Systems
  1075. Versameb
  1076. Verseau Therapeutics
  1077. Vertex Pharmaceuticals
  1078. Vetter Pharma
  1079. VGXI
  1080. Vibalogics
  1081. VIDO
  1082. Vifor Pharma
  1083. Vigene Biosciences
  1084. Vineti
  1085. Vir Biotechnology
  1086. Viralgen
  1087. Virchow Biotech
  1088. Virion Therapeutics
  1089. ViroCell Biologics
  1090. Virovek
  1091. Viscofan
  1092. VIVEbiotech
  1093. Voyager Therapeutics
  1094. VVector Bio
  1095. W.L. Gore & Associates
  1096. WACKER
  1097. Waisman Biomanufacturing
  1098. Walvax Biotechnology
  1099. Warburg Pincus
  1100. Wheeler Bio
  1101. Winclove Probiotics
  1102. WuXi AppTec
  1103. WuXi Biologics
  1104. Wuxi Griffin
  1105. Xbrane Biopharma
  1106. Xenetic Biosciences
  1107. XL-protein 
  1108. Xpress Biologics
  1109. Xyphos Biosciences
  1110. Yapan Bio
  1111. Yinjia Biosciences
  1112. Yposkesi
  1113. Yuhan
  1114. Zealand Pharma 
  1115. Zelluna Immunotherapy
  1116. Zencore Biologics
  1117. Zhejiang Hisun Pharmaceutical
  1118. Zhejiang Teruisi Pharmaceutical
  1119. Zhittya Genesis Medicine
  1120. Zumutor Biologics
  1121. Zymeworks
  1122. ZyVersa Therapeutics

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com